Almost three weeks after the hurricane, just 16 percent of electricity service has been restored to the island.
Big Pharma went on a political spending spree the next day.
More company executives are leaving President Donald Trump’s manufacturing advisory board, in protest of his delay to condemn the white supremacism displayed in Charlottesville.
After more than a half-dozen members announced their departures, the president said he would end the manufacturing panel.
Instead of denouncing neo-Nazis early Monday, Trump denounces a CEO criticizing him for not personally denouncing neo-Nazis.
A recently introduced bill has almost no chance of passing in a GOP-controlled Congress. But it's a victory for clear thinking over inertia.
Women are still dying from preventable causes related to pregnancy and childbirth.
There are few assemblages more tainted than a board of directors of a large public corporation. It is a putrid web of interlocking
An international vaccine coalition took an unprecedented step this week.
Our homes and our offices are getting smarter by the day as the Internet of Things -- the internet of everything -- becomes increasingly ubiquitous. Soon we'll be able to control even the heat and light that streams through our windows with just the push of a button.
Speaking with Dr. Priya Agrawal, Executive Director of Merck for Mothers, for this latest interview in our Maternal Health Heroes Summer Series, I instinctively realized that she is not only a gifted communicator with a passion for women's health, but also an infectious advocate for safe motherhood both in the United States and worldwide.
Tamara Jacobs knows what she's talking about when it comes to moving ahead in the business world. When Fortune 500 companies like Pfizer, Johnson & Johnson, Bayer, Merck, Novartis, Revlon, and others need advice with their branding and image, they call Tamara.
"Disability is represented in all other dimensions of human difference including race, faith, and sexual orientation. Almost everyone will experience a temporary disability at some point in their lives and likely end up with one or more life-long disabilities as they grow older."
Pfizer and the plaintiffs agreed to delay the trial until after the Halliburton decision. In a letter to the court, Pfizer